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Abstract
The integrity of the articular cartilage is necessary for the proper functioning of the diar-
throdial joint. The self-repair capacity of this tissue is very limited and, currently, there 
is no effective treatment capable of restoring it. The degradation of the articular cartilage 
leads to osteoarthritis (OA), a leading cause of pain and disability mainly among older 
people.
Different cell treatments have been developed with the aim of forming a repair tis-
sue with the characteristics of native articular cartilage, including cellular therapy 
and tissue engineering. Cell therapy-based approaches include bone marrow-stimu-
lating techniques, implants of periosteum and perichondrium, ostechondral grafting 
and implantation of chondrogenic cells as chondrocytes, mesenchymal stem cells or 
induced pluripotent stem cells. In tissue engineering-based approaches cell-free scaf-
folds capable of recruiting endogenous cells or chondrogenic cell-loaded scaffolds may 
be used.
However, despite the numerous treatments available nowadays, no technique has been 
able to consistently regenerate native articular cartilage in clinical trials. Although many 
cell therapy and tissue engineering studies have shown promising results and clinical 
improvement, these treatments generate a fibrocartilaginous tissue different from native 
articular cartilage. More research is needed to improve cell-based approaches and prove 
its efficacy
Keywords: regenerative medicine, chondrogenic cells, mesenchymal stem cells (MSCs), 
induced pluripotent stem cells (iPS), scaffolds
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1. Introduction
The integrity of the structure of the articular cartilage is necessary for the proper functioning 
of the diarthrodial joint. Articular hyaline cartilage provides a resistant, smooth, and lubri-
cated surface, which avoids friction between bones. Thus, hyaline cartilage absorbs and mini-
mizes the pressures produced in the movement of the joint, allows bones to glide over one 
another with minimal friction, and facilitates the coupling between articular surfaces. Due to 
its elasticity, articular cartilage absorbs an important part of the compression force, reducing 
the load supported by the underlying bone structure [1–3].
Traditionally, osteoarthritis (OA) was defined as a degenerative joint disease, characterized by 
the alteration in the integrity of the articular cartilage [1]. Nowadays, it is known that although 
the degradation of articular cartilage is the central event in the pathogenesis of OA, synovial 
tissue and subchondral bone also participate in the onset and development of this disease 
[4]. The degree of compromise of these components of the joint leads not only to variability 
between the clinical profiles of patients, but also between different joints of the same patient 
[5]. On this basis, the Osteoarthritis Research Society International (OARSI) has defined OA as 
a heterogeneous disorder of movable joints, manifested as genetic, metabolic, and inflamma-
tory changes in the joint, as well as anatomic and/or physiological conditions that may lead to 
the symptoms associated with the disease. OA is characterized by cell stress and extracellular 
matrix degradation initiated by micro- and macro-injury that activates maladaptive repair 
responses including pro-inflammatory pathways of innate immunity [6]. OA is one of the 
most common chronic health conditions and a leading cause of pain and disability among 
adults [2, 7]. OA is one of the most prevalent diseases in older people and its incidence, which 
increases with age, is expected to rise along with the median age of the population [3, 8].
The self-repair capacity of articular cartilage is very limited as it is an avascular and aneural 
tissue. Due to this absence of vascularity, progenitor cells present in blood and marrow can-
not enter into the damaged region to influence or contribute to the reparative process [9, 10]. 
In addition, because of aneurality, chondral lesions are not detected, and thus patients are not 
medically treated until more severe lesions are formed [11, 12].
Currently, there is no effective treatment capable of restoring the physiological properties of 
the osteochondral unit (Figure 1A) [13, 14] and the prosthetic replacement is necessary at the 
final clinical stage (Figure 1B) [6]. Different cell treatments have been developed with the aim 
of forming a repair tissue with structural, biochemical, and functional characteristics equiva-
lent to those of native articular cartilage (Figure 2). Scientists have sought several different 
ways to repair articular cartilage after traumatic damage, which can lead to secondary OA or 
degeneration of the cartilage [13, 15–17].
It is necessary to highlight that “repair” refers to the restoration of a damaged articular surface 
with the formation of a neocartilage tissue, which resembles to the native cartilage and “regen-
eration” refers to the formation of a tissue indistinguishable from the native articular cartilage 
[16]. Cellular therapy (using cells) and tissue engineering (combining cells, scaffolds, and bioac-
tive factors) have emerged as alternative clinical approaches. However, despite the numerous 
treatments available nowadays, no technique has been able to consistently regenerate normal 
hyaline cartilage in clinical trials [3, 18]. Long-term follow-up studies are expected to be per-
formed in the coming years to confirm safety and effectiveness of these new approaches [3].
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2. Cell therapy
Cell therapy is a relatively new approach based on the regeneration or repair of a damaged 
tissue using autologous or allogenic cells.
2.1. Marrow stimulating techniques
Bone marrow stimulating techniques (MSTs) are based on the use of endogenous mesenchy-
mal stromal cells (MSCs). This type of technique is used in the treatment of chondral lesions 
with less of 15 mm of diameter [19].
Penetration of subchondral bone is among the oldest and still the most commonly used 
method to stimulate regeneration of neocartilage [16, 20]. Arthroscopic techniques like drill-
ing, abrasion arthroplasty or microfracture are different tools to perforate the subchondral 
Figure 1. Images showing (A) healthy knee joint and (B) prosthetic joint replacement.
Figure 2. Diagram showing an overview of the alternative treatments for osteochondral damage.
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bone [12], allowing MSCs and growth factors from the bone marrow to infiltrate the lesion 
[15]. A blood clot is formed in the defect, acting as a scaffold and mediating the inflammatory 
response (through cytokines) [19].
However, it was described that endogen bone marrow angiogenic factors favor osteogenesis, 
instead of chondrogenesis, of bone marrow MSCs [11]. Generated repair tissue frequently 
ends up degenerating [21] and usually presents type I collagen (fibrocartilage phenotype) and 
lacks hyaline cartilage viscoelastic properties [22].
2.2. Tissue grafts
Tissue grafts have potential benefits in cartilage repair since they contain cell populations 
with chondrogenic capacity.
2.2.1. Implants of periosteum and perichondrium
In the 90s, autologous strips of perichondrium were used to treat chondral defects [23, 24]. 
Periosteum and perichondrium contain MSCs that are capable of chondrogenesis and act as 
a biological membrane [16]. However, the ability of periosteum MSCs to proliferate and dif-
ferentiate into chondrocytes decreases with age [25].
The clinical outcomes of perichondrium implants are similar to those of subchondral perfora-
tion [26]. Calcification of the periosteum grafts had been mentioned as a problem in the long 
term [16].
2.2.2. Mosaicplasty
Autologous mosaicplasty is widely used for treating chondral and osteochondral defects. The 
most used technique is the osteochondral autologous transplantation (OAT), which consists 
in the translocation of osteochondral cylinders from not loading areas to the affected areas of 
the joint [15].
Even though good to excellent short-term subjective results were obtained, clinical and radio-
logical midterms to long-term outcomes of mosaicplasty were moderate. Further limitations 
are donor-site morbidity, technical difficulty, special equipment, lesion size, and fibrocarti-
laginous repair [16, 27]. OAT might be more appropriate for lesions smaller than 2–3 cm2 [28].
Another problem is the lack of congruence between the osteochondral cylinders implanted 
and the lesion area, and the differences in cartilage height of the defect and surrounding 
native cartilage, altering the distribution of stress and compression forces [16, 27].
Allogenic mosaicplasty has shown successful outcomes and its main advantage over auto-
graft transplantation is the lack of donor-site morbidity. Nevertheless, the amount of trans-
planted bone has to be minimum because the allograft failure is mostly due to collapse of the 
subchondral bone [22].
Nowadays, synthetic cylindrical plugs for implant similar to OAT exist but studies have 
shown universal failure to incorporate these plugs into the subchondral bone, with formation 
of cysts [22].
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In addition to fresh osteochondral grafts, particulated cartilage grafts, which are formed by 
combining fragments of cartilage with fibrin glue, may also be used. Superficial chondrocytes, 
released from the extracellular matrix as a consequence of the fragmentation of the cartilage, 
produce additional extracellular matrix that integrates the particulate graft with native carti-
lage and fills the defect [29].
2.3. Implantation of cells with chondrogenic capacity
Chondrogenic potential of different cell types (Figure 3) was tested for hyaline cartilage repair.
2.3.1. Autologous chondrocyte implantation
The autologous chondrocyte implantation (ACI) was firstly described by Peterson et al. [30]. 
This technique consists of harvesting a cartilage piece from a low-weight-bearing area of the 
joint and culture-expanding the chondrocytes to implant into the lesion. The lesion is sealed 
with autologous periosteum to avoid cell loss.
ACI is only applicable to small size (3–4 cm2) focal lesions surrounded by healthy cartilage 
[15, 28]. Other limitations are dedifferentiation of chondrocytes during culture expansion, the 
low amount of chondrocytes obtained and multiple surgical procedures involved [31, 32]. 
Further, donor-site morbidity of cartilage and bone for chondrocyte and periosteum obtain-
ing was observed [15, 33, 34].
ACI is considered superior to MSTs regarding the quality of the repaired tissue, although 
there are conflicting results [28].
Figure 3. Diagram showing the different cell sources, most commonly used in cartilage treatment using cell therapy: 
chondrocytes (left), mesenchymal stromal cells (middle), and induced pluripotent stem cells (right).
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2.3.2. Chondrospheres
The technique of chondrospheres consists of the generation and implantation of spheroids of 
autologous or allogenic articular chondrocytes [29]. Autologous chondrocytes are obtained 
from undamaged articular cartilage, expanded in vitro, and condensed in order to form 
spheroids, which then are coalesced. Chondrospheres have shown to be able to adhere, inte-
grate into hyaline cartilage defect and produce cartilaginous extracellular matrix in mouse, 
mini pig, and horse cartilage defect models, as well as in artificial defects in human cartilage 
explants [35–37]. A phase III clinical trial is currently ongoing in Germany and Poland to 
investigate the efficacy of this technology compared to microfracture in the treatment of car-
tilage defects of knee joints [38].
2.3.3. Mesenchymal stromal cells
Human MSCs are nonhematopoietic multipotent progenitor cells with long-term self-renewal 
ability and the capacity to differentiate along multiple cell lineages, including cartilage, as 
well as immunomodulatory features [39–41]. MSCs are responsible for normal tissue renewal 
and for response to injury and may be an alternative to chondrocytes for the development of 
new therapeutic approaches for the treatment of cartilage defects.
In vitro and in vivo studies of clonally derived MSCs demonstrated that these cells consist of 
subsets that present different surface markers expression and different capacities for cellular 
differentiation [42]. These cells are considered a potential cell source for cell therapy since 
they can be easily collected from various tissues such as bone marrow [43], adipose tissue [44], 
synovial membrane [42], and amniotic membrane [45], among others. However, the equiva-
lence of chondrogenic differentiation potential of MSCs derived from different tissues is a 
matter of considerable debate [46].
For cell therapy approaches, either autologous or allogenic MSCs can be used. MSCs do not 
express major histocompatibility complex class II (MHC II) and its co-stimulatory molecules, 
and barely express major histocompatibility complex class I (MHC I), so that they do not pro-
duce alloreactivity, avoiding rejection problems. This feature turns MSCs into a feasible cell 
source for allogenic transplantation [40, 47].
The therapeutic potential of autologous MSCs derived from different tissues to stimulate the 
regeneration of cartilage in OA has been reported in several preclinical studies [48, 49]. Bone 
marrow-derived MSCs suspended in hyaluronic acid and administrated by intra-articular 
injection have been used to promote cartilage repair in animal models such as guinea pig, mini 
pig, goat and donkey, leading to improvement in cartilage regeneration, less cartilage destruc-
tion and reduced osteophyte formation [50–53]. MSCs derived from other sources have also 
been used; for example, transplantation of synovial MSCs was used to repair osteochondral 
defects in rabbits [54], and intra-articular injection of adipose-derived MSCs was used to treat 
chronic osteoarthritis in dogs, showing significant improvement in MSCs-treated joints [55].
One of the MSCs transplantation techniques for cartilage focal lesions is a variation of ACI in 
which bone marrow MSCs are injected into defects and closed with periosteal membrane to 
be differentiated toward chondrocytes [56]. The first clinical study using MSCs to treat OA 
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was performed by Wakitani et al. [57]. In this study, bone marrow-derived MSCs were trans-
planted into the articular cartilage defect and covered with autologous periosteum. Although 
the arthroscopic and histological grading score was better in the cell-transplanted group than 
in the control one, the clinical improvement was not very clear. Since then, several clinical 
studies have been performed, mainly using intra-articular injection of autologous bone mar-
row-derived MSCs, showing some degree of improvement in terms of clinical outcomes and 
repaired cartilage tissue quality [58–60]. However, several studies described a lack of engraft-
ment into cartilage defects [61] and it is important to highlight that most of the clinical trials 
are I and I/II phases, indicating the immaturity of MSC clinical applications in OA [49].
Limitations of this approach are that culture expansion is not avoided, cell yield is often low 
and MSCs differentiation capacity decreases with age of the donor [21]. This is a problem in 
regenerative therapies for degenerative diseases such as OA, where most of patients are aged 
[61]. Given that the age of patient and the size of the lesion affect the outcome, the cut-off points 
for the risk of failure have been suggested at age greater than 60 years and lesion size larger than 
6.0 cm2 [28].
2.3.4. Mesenchymal stromal cells combined with autologous chondrons
A novel cell therapy approach is based on combining autologous chondrocytes in their pericel-
lular matrix (chondrons) and allogenic MSCs, which was called Instant MSC Product accom-
panying Autologous Chondron Transplantation (IMPACT) and performed by De Windt et al. 
[62]. In this phase I clinical trial, patients with focal cartilage defects were treated using a mix 
of 80–90% allogenic MSCs and 10–20% autologous chondrons combined with fibrin glue. In 
this approach, chondrons are “recycled” from debrided cartilage instead of being harvested 
from a low-weight-bearing area of the joint, as occurring in ACI. The combination of this recy-
cled chondrons with allogenic human bone marrow MSCs stimulates cartilage regeneration 
and provides clinical improvement. Surprisingly, although the co-implantation of chondrons 
and MSCs provides better results in comparison with implantation of chondrons or MSCs 
alone [63], no allogenic cells were detected in the repaired cartilage after 1 year, suggesting 
that MSCs have trophic effects that stimulate chondrons to regenerate cartilage. The quality of 
the repaired tissue and the clinical outcome using the IMPACT technique was similar or even 
superior in comparison with ACI. Furthermore, IMPACT technique presents the advantage 
of allowing to perform both surgeries on the same day (the extraction of cartilage and the 
implantation of cells) [62].
2.3.5. Induced pluripotent stem cells
Pluripotent cells could provide an unlimited and renewable cell source that can be induced to 
differentiate into any cell type. In fact, pluripotent cells of embryonic origin [61, 64], embry-
onic human stem cells (hESCs), or induced to pluripotency [65], induced pluripotent stem 
cells (iPSCs), have shown to produce cartilage under specific conditions. iPSCs have been 
generated from adult cells (Figure 4A) using defined factors (Figure 4B) [66]. These cells pres-
ent similar morphology (Figure 4C), proliferation capacity, genetic expression and epigenetic 
pattern, and pluripotency characteristics to hESCs [66, 67].
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iPSCs seem to be an alternative tool to chondrocytes for cartilage repair as they can be expanded 
before starting their differentiation (using or not embryoid bodies formation) toward chon-
drocytes (Figure 4D). Then, iPSC-derived chondrocytes can be cultured in three-dimensional 
culture with scaffold (Figure 4E, w/Scaffold), or cultured without a scaffold (Figure 4E, w/o 
Scaffold), to create cartilaginous tissues in vitro before transplantation to repair large defects 
[68].
In addition, iPSCs seem to be an alternative tool to MSCs for cartilage repair. After in vitro 
chondrogenesis, iPSCs showed lower hypertrophic markers than MSCs [69]. The risk of iPSCs 
teratoma formation in cell therapy or tissue engineering can be avoided using pre-differen-
tiated cells before implantation [70, 71]. Also, the use of iPSCs avoids the problem of in vivo-
age-dependent and in vitro-passage-dependent MSC senescence [72].
Yamashita et al. [73] optimized a protocol of chondrogenic differentiation using human iPSCs 
to form homogenous cartilaginous particles. After the transplantation of these chondrogenic 
Figure 4. Scheme representing the role of iPSCs in tissue engineering. (A) Harvesting somatic cells from the patient. (B) 
Reprogramming the cells using the factors Oct4, Sox2, Klf4, and c-Myc. (C) iPSc colony obtained after reprogramming. 
(D) Embryoid bodies (EB) formation. (E) Differentiation of the iPSc toward chondrocytes with (W/) or without (W/O) 
scaffold.
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particles into joint surface defects in immunodeficient rats and immunosuppressed mini pigs, 
they observed cartilaginous neotissue with potential for integration into native cartilage.
Nowadays, there are no clinical studies published about cartilage cell therapy using iPSCs. 
Although cell therapy or tissue engineering using iPSCs are promising tools, their clinical use 
is not legalized either by the scientific community or by existing international legislation yet, 
except in Japan.
3. Tissue engineering
The lack of efficient treatments for cartilage repair motivates the researchers to develop, 
by tissue engineering, biological tissue substitutes that can be implanted to replace the 
affected area of the joint [74]. Tissue engineering is not widespread yet in surgical proce-
dures, although there are many combinations of different cells and supports being tested 
both in vitro and in vivo.
In this way, different strategies were developed for cartilage regeneration, based on the use 
of scaffolds and endogenous or exogenous cells. Whereas in in vitro studies scaffolds are 
usually combined with cells and bioactive factors, in most in vivo studies the scaffolds are 
used only combined with cells because those factors are present in the joint (e.g., AMIC 
described below).
In vitro administration of growth factors (transforming growth factor 1 or 3, bone morphogenetic 
proteins 2 or 7, and insulin growth factor 1, among others) have been used to induce chondro-
genic differentiation of MSCs and iPSCs. However, the effect of application of these molecules 
is dose, timing of administration and cell type-dependent [75]. That is why, in recent years, scaf-
folds were functionalized with bioactive factors or other molecules for in vivo cartilage therapies, 
as a delivery system [76] or stimulation for MSCs. For example, the addition of proteoglycans to 
collagen biomaterials had improved bone marrow MSCs chondrogenic differentiation [43, 77].
A broad variety of biomaterials have been successfully developed to support proliferation, 
infiltration, or differentiation of allogeneic transplanted or endogenous MSCs to achieve func-
tional tissue restoration [78]. Scaffolds/biomaterials should be a porous three-dimensional 
matrix that allow cell migration, adhesion and growth, and support the organization of the 
growing tissue [79].
However, despite the diffusion of new tissue-engineering techniques and the high number 
of scaffolds that have been developed and investigated for cartilage regeneration, the ideal 
matrix material has not been identified yet. Cartilage-engineering strategies have produced 
promising in vitro data, seeding chondrogenic cells on biomaterials with growth factors. 
However, thus far, no approach has led to the generation of long-term in vivo replacement 
tissue identical to native hyaline cartilage. There are different factors for the lack of stable 
functional tissue as inflammatory stress or biophysical stimuli [80].
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3.1. Cell-free scaffolds and endogenous cells
Cell-free scaffolds are developed for one stage procedure techniques, since they can be 
implanted alone to attract the endogenous cells. In this case, the aim of using scaffolds is 
to obtain a suitable microenvironment to recruit and mobilize the host cells, from either the 
blood or a tissue specific (bone marrow, synovial fluid…) niche for self-repair. Several stud-
ies have detected the recruitment of endogenous synovial cells [81, 82] or exogenous-injected 
MSCs [50] in injured areas after the implantation of empty scaffolds.
Implantation of cell-free scaffolds avoids the issues around the in vitro cell culture process, as 
exogenous cell transplantation is not required. However, clinical results after implantation of 
cell-free scaffolds for OA treatment are few [3].
3.1.1. Autologous matrix-induced chondrogenesis
The autologous matrix induced chondrogenesis (AMIC) is a second generation MSTs. This is 
a one-step procedure combining subchondral microfracture with the attachment of a collagen 
scaffold to the lesion. The initially formed blood clot as produced by microfracturing is pro-
tected by the collagen scaffold [83]. The collagen scaffold is thought to stabilize the blood clot, 
helping to promote early mechanical stability and cartilage regeneration [29]. More complex 
scaffolds have also been tested in AMIC studies, for example, a biphasic scaffold consisting of 
calcium triphosphate in the osseous region and poly(lactic-co-glycolic acid) in the cartilaginous 
region [84].
Even though donor-site morbidity due to removal of periosteum from tibia is avoided, AMIC 
has similar clinical outcomes to ACI [85].
3.1.2. Scaffold-based autografts
Another approach is the use of scaffold-based autografts, in which harvested cartilage is 
mechanically minced and uniformly affixed to a biodegradable scaffold, using fibrin glue; 
then, the scaffold with the cartilage fragments is transferred to the lesion. When compared to 
microfracture, this scaffold-based autograft procedure resulted in an improvement of func-
tional outcomes and cartilage development [86].
3.1.3. Decellularized extracellular matrix scaffolds
Decellularized extracellular matrix may be used as a scaffold with the potential to retain the 
bioactive factors needed to support specific tissue formation at the implantation site [87]. 
Cartilage matrix can be harvested from allogenic sources, then decellularized and used as 
a scaffold. This approach leads to the improvement of neocartilage formation in preclinical 
models, in comparison with the living-cartilage implantation [88]. One of the drawbacks of 
this technique is that the protocols required to decellularization of cartilage also imply some 
degree of destruction of extracellular matrix components [89]. Decellularized cartilage matrix 
has been used to treat osteochondral defects in a horse model, obtaining repair of both the 
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bone and cartilage phases [87]. Beside the tissue decellularization, extracellular matrix scaf-
folds can also be obtained from cultured cells [90].
3.2. Cell-loaded scaffolds
3.2.1. Matrix-associated chondrocyte transplantation
The matrix-associated chondrocyte implantation/transplantation (MACI or MACT) is a sec-
ond generation ACI, which includes the employment of a bilayer collagen membrane [91]. 
Essentially, the concept is based on the use of biodegradable polymers as temporary scaffolds 
for in vitro growth of cells and their subsequent transplantation into the defect site. In this 
case, autologous chondrocytes are previously seeded in the scaffold before implantation into 
the lesion [12, 83]. Other types of scaffolds (hydrogels, fibrous scaffolds, decellularized ECM, 
or composites) were later used [85].
MACI presents lower rates of graft hypertrophy than first-generation ACI [92].
3.2.2. Mesenchymal stromal cells on scaffolds
Wakitani et al. [93] observed that MSCs embedded in a collagen gel could differentiate in 
in vivo animal models. Since these first studies, thousands of works were carried out using 
different types of scaffolds (hydrogels, sponges…), cells, and approaches for chondrogenic 
scaffolding.
Several in vivo studies tried to replicate the distinct osteochondral zones using tri- or bi-lay-
ered scaffolds of different composition and/or bioactive factors combined with MSCs. MSCs 
combined with scaffolds appear to engraft and contribute to cartilage repair, while MSCs 
injected as a free suspension into the joint do not engraft into the cartilage [61]. This happens 
because scaffolds can transport cells into the lesion and provide the proper environment for 
cell differentiation [75, 94].
It was described that cartilage tissue engineering from differentiation-induced in vitro MSCs has 
an inferior quality to that engineered from chondrocytes [95]. However, human amniotic MSCs 
with human amniotic membrane (as scaffold) showed better reparation in an in vitro repair 
model when compared with bone marrow MSCs and chondrocytes, and demonstrated good 
adhering capacity to the native cartilage [45]. Also, our group obtained good results using bone 
marrow MSCs and collagen/heparan sulfate scaffolds in an in vitro repair model (Figure 5) [96].
3.2.3. Induced pluripotent stem cells on scaffolds
Although tissue-engineering studies using iPSCs are scarce, several studies have shown their 
potential in chondral repair [21]. Liu et al. [48] have tested the chondrogenesis of murine cells 
derived from single embryoid bodies. After seeding these cells on polycaprolactone/gelatin 
scaffolds, they showed a good chondrogenic capacity.
Nowadays, 3D bioprinting into cartilage using iPSCs and bioinks (that act as scaffolds) is 
being developed [97].
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4. Gene therapy
Gene therapy involves the over-expression of the appropriate gene (anabolic factors, chon-
droinductor, or anti-inflammatory molecules) and cell type (chondrocytes or chondrogenic 
cells) for their use in cell therapy and tissue engineering.
Nowadays, no gene products have been approved for OA treatment and few clinical trials 
have been conducted. At present, only TGF-β gene therapy has been clinically investigated in 
USA and Korea [3].
5. Conclusions
Although many studies of cell therapy and tissue engineering have shown clinical and func-
tional improvement in joints, these treatments generate a fibrocartilaginous tissue that is dif-
ferent from hyaline articular cartilage. The ability to regenerate articular cartilage that resists 
the degeneration process still remains elusive.
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